ARTIFICIAL BLOOD: FROM CONCEPT TO CLINICAL PROMISE

Authors

  • Esmahan Faed Albadwi

DOI:

https://doi.org/10.25215/0557983827.28

Abstract

The global shortfall in donor blood has intensified the search for synthetic alternatives capable of replicating the oxygen-carrying and homeostatic functions of whole blood. This chapter examines the principal categories of artificial blood currently under investigation: haemoglobin-based oxygen carriers (HBOCs), lipid-encapsulated haemoglobin vesicles (HbV), perfluorocarbon-based oxygen carriers (PFOCs), and fully synthetic engineered erythrocytes. For each category, the underlying chemistry, clinical development trajectory, and safety profile are discussed. Persistent challenges—vasoconstriction arising from nitric oxide scavenging, short circulatory half-lives, manufacturing scalability, regulatory complexity, and biocompatibility—are examined in relation to current solutions. Emerging directions, including nanotechnology-enabled carriers, synthetic-biology-derived proteins, and AI-assisted personalisation, are also explored. The chapter concludes that, although no universally approved artificial blood product exists, the field is undergoing a substantive technological transition that positions next-generation products to surpass the limitations of donor-derived blood in targeted clinical applications.

Published

2026-07-03